The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today recommended the two-dose Novavax COVID-19 vaccine as a COVID-19 vaccine primary series for emergency use in adults. If the CDC endorses ACIP’s recommendation, the protein-based vaccine would offer an option to individuals who may have an allergic reaction to or prefer not to receive an mRNA vaccine. The FDA last week authorized the vaccine for individuals age 18 and older. The departments of Health and Human Services and Defense this month secured 3.2 million doses of the vaccine to give states, federal pharmacy partners and federally qualified health centers. The vaccine can be stored at 2-8 degrees Celsius (about 36-46 degrees Fahrenheit), enabling the use of existing vaccine supply and cold chain channels.

Related News Articles

Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
There have been 1,024 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
There have been 1,001 confirmed cases of measles across the U.S. so far in 2025, according to the latest data from the Centers for Disease Control and…
Headline
Though seasonal flu activity is low or minimal across the country, 216 pediatric deaths associated with seasonal influenza virus infection have been tallied so…
Headline
The U.S. has had 935 confirmed cases of measles so far this year, according to the latest data from the Centers for Disease Control and Prevention. Cases have…
Headline
There have been 884 confirmed cases of measles nationwide so far this year, with cases reported by 29 states, according to the latest data from the…